NEW YORK, The non-small cell lung cancer drugs market will be driven by factors such as increasing prevalence and incidence of non-small cell lung cancer.
The market is expected to grow by USD 30.23 bn from 2021 to 2026, progressing at a CAGR of 17.1% during the forecast period, according to Technavio. The report offers an up-to-date analysis as well as exact growth variance and the Y-O-Y growth rate.
Non-small Cell Lung Cancer Drugs Market 2022-2026: Scope
The non-small cell lung cancer drugs market report covers the following areas:
Non-small Cell Lung Cancer Drugs Market sizeNon-small Cell Lung Cancer Drugs Market trendsNon-small Cell Lung Cancer Drugs Market industry analysis
Non-small Cell Lung Cancer Drugs Market 2022-2026: Segmentation
By product, the market has been segmented into biologics, small molecule targeted therapy, and chemotherapy. The biologics segment will have significant market share growth during the forecast period. The growth of the market is driven by the increased prevalence of non-small cell lung cancer and the availability of biologics to treat the disease.
By geography, the market has been segmented into North America, Europe, Asia, and Rest Of World (ROW). North America will have the highest market share growth during the forecast period.
Non-small Cell Lung Cancer Drugs Market 2022-2026: Drivers and Challenges
The increasing prevalence and incidence of non-small cell lung cancer is driving the non-small cell lung cancer drugs market growth. This is due to the rise in risk factors such as cigarette smoking, secondary smoking, air pollution, and occupational exposure. In Asian countries, rapid industrial development and sub-urbanization, and disease patterns are leading to the increased prevalence of non-small cell lung cancer.
Factors such as high cost of treatment may challenge the market growth. Non-small cell lung cancer can be treated by surgery, radiation therapy, chemotherapy, targeted therapies, and immunotherapy. However, the cost of these treatments is very high. Immunotherapy for non small cell lung cancer may include immune checkpoint inhibitors such as OPDIVO, KEYTRUDA, TECENTRIQ, and IMFINZI. The overall cost of treatment, including diagnosis, hospitalization, outpatient office visits, and a monthly initial treatment phase, is USD 46,000 per patient.
Non-small Cell Lung Cancer Drugs Market 2022-2026: Vendor Analysis
We provide a detailed analysis of around 25 vendors operating in the Non-small Cell Lung Cancer Drugs Market, including AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bayer AG, BeiGene Ltd., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck and Co. Inc., Merck KGaA, Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, and Takeda Pharmaceutical Co. Ltd. among others.
Non-small Cell Lung Cancer Drugs Market 2022-2026: Key Highlights
CAGR of the market during the forecast period 2022-2026Detailed information on factors that will assist non-small cell lung cancer drugs market growth during the next five yearsEstimation of the non-small cell lung cancer drugs market size and its contribution to the parent marketPredictions on upcoming trends and changes in consumer behaviorThe growth of the non-small cell lung cancer drugs marketAnalysis of the market’s competitive landscape and detailed information on vendorsComprehensive details of factors that will challenge the growth of non-small cell lung cancer drugs market vendor
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
This article was shared with Prittle Prattle News as a Press Release by PRNewswire.
